Alcresta Launches With Dynamic Business Model; Raises $10M Series A
This article was originally published in The Pink Sheet Daily
Executive Summary
Former Alnara executives have come together with the company’s previous investors to launch two start-ups focusing on enzyme therapies.
You may also be interested in...
Alcresta Infused With $10M Series B To Get First Product To Market
The Massachusetts nutritionals company has guaranteed it can transition from a development company to a commercial company without the help of a partner due to a recent infusion of cash but hopes to strike partnerships for certain indications and regions once the product gets to market.
Alcresta Infused With $10M Series B To Get First Product To Market
The Massachusetts nutritionals company has guaranteed it can transition from a development company to a commercial company without the help of a partner due to a recent infusion of cash but hopes to strike partnerships for certain indications and regions once the product gets to market.
Financings Of The Fortnight: Thiel Looks To Bridge The Pre-Venture Capital Funding Gap For Biotech
Plus news on recent financing activity by Alcresta, Alder Biopharmaceuticals, H.I.G Capital and Supernus Pharmaceuticals.